We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Healthcare-Associated Pneumonia Pathogens Testing Has Limited Success

By LabMedica International staff writers
Posted on 05 Oct 2009
Testing for pathogens in patients with healthcare-associated pneumonia (HCAP) provides results in less than one-third of cases, according to recent preliminary findings.

In a six-year retrospective study, a pathogen was isolated from 31% of samples taken from nearly 1,600 patients with HCAP, according to Karl Madaras-Kelly, M.D., from the Veterans Administration (VA) Medical Center (Boise, ID, USA).

The finding is important because guidelines for treatment in such cases suggest broad antibiotic therapy with several drugs, followed by modification once a pathogen is identified, Dr. More...
Madaras-Kelly reported her findings at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 2009 in San Francisco, CA, USA. "If you can't identify a pathogen," Dr. Madaras-Kelly said, "you can't really stop [unsuitable] drugs."

The study period--from 2003 through 2008--covers the period before and after the 2005 guidelines were issued by the Infectious Diseases Society of America. The investigators examined records of all patients admitted for pneumonia at six VA medical centers in the northwestern United States, finding 1,568 who met criteria for healthcare-associated pneumonia. Of those, according to Dr. Madaras-Kelly, 92.6% provided one or more cultures, including 81.8% of the total from blood, 49.7% from sputum, and 1.5% from bronchoscopy. However, out of those 1,452 patients with a culture, only 486 (31%) had a pathogen isolated, he noted.

There was no significant year-by-year difference in the proportions with an isolated pathogen, according to Dr. Madaras-Kelly. However, some of the six study sites did better in collecting quality cultures--with result ranges from 6.3-43.6%. The differences were significant at p < 0.001. Dr. Madaras-Kelly noted that clinicians "do adjust treatment when they have a quality culture, but the majority of patients don't have a good culture."

The implications, according to Dr. Madaras-Kelly, include a need to focus on retrieving good quality cultures. "And we also need better methods to diagnose pneumonia because cultures are expensive," he added.

The study's findings have to be interpreted in light of other research suggesting that a pathogen is isolated only 40% of the time in community-acquired pneumonia, according to Lindsay Grayson, M.D., from Austin Hospital (Melbourne, Australia). Dr. Grayson, one of the ICAAC meeting's program cochairs, was not part of the research.

One reason for the failure rate is that patients are frequently given antibiotics before the testing. "[It's] not enough to cure them but enough to confuse the cultures," Dr. Grayson said, and a similar issue may arise with healthcare-associated pneumonia. He stated that the study calls into question "the timing of cultures in relation to any recent antibiotics" and stressed the value of accurate samples.

Related Links:

VA Medical Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.